Grifols (GRFS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

GRFS Grifols

Watchlist

7.820
+0.140+1.82%

Close Dec 24 13:00 ET

7.820
0.0000.00%

Post 17:01 ET

5.31BMarket Cap31.28P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Grifols Closes Private Placement for EUR1.3 Billion Notes
MT NewswiresDec 23 04:44 ET
Moody's Assigns Ratings, Positive Outlook on Grifols
MT NewswiresDec 18 08:11 ET
Fitch Affirms Grifols Rating on Forecast of EBITDA Growth
MT NewswiresDec 17 23:47 ET
Grifols Price Target Lowered to EUR 15.40 From EUR 15.50 at Berenberg
TipRanksDec 16 12:15 ET
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
MT NewswiresDec 16 11:10 ET
Grifols (0RDU) Receives a Buy From Berenberg Bank
TipRanksDec 16 02:17 ET · Ratings

Comments

Trytosaveabit

Oct 29 07:12

News

$Grifols (GRFS.US)$ Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution
Benzinga· 3 mins ago

Trytosaveabit

Oct 3 07:12

If any seen that for the 40 seconds it was posted!

$Grifols (GRFS.US)$ I removed the post because i think the PR was tagged to the wrong ticker by the NEWS OUTLETT! And i want to be more safe and check a bit more!

Trytosaveabit

Aug 21 03:57

A bit added to older PR ( seeking backing ) is the new!

$Grifols (GRFS.US)$ Investing.com -- Shares of Grifols SA (BME:GRLS) (NASDAQ:GRFS) rose on Wednesday after Bloomberg News reported that Brookfield Asset Management (TSX:BAM) is seeking bank backing for up to €9.5 billion in debt to facilitate its potential take-private acquisition of the Spanish pharmaceutical producer

Trytosaveabit

Jul 29 07:04

News

$Grifols (GRFS.US)$ Benzinga· 2 mins ago
FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients

Kevin Travers

Jul 8 09:50

Columns Fresh Highs Before Flat Trading, Last Week Before Q2 Earnings | Herd on Wall Street

Morning traders, it is the final slow week before a new earnings season begins Thurday with $Delta Air Lines (DAL.US)$ and properly on Friday with $JPMorgan (JPM.US)$.
Welcome to the end of the dog days of summer for a while; my name is Kevin Travers, and here are stories from the moomoo herd on Wall Street today.
$Intel (INTC.US)$ traded higher after the firm said it had bypassed Vietnam for a $3.3B project and in...